Group 1 - The company provides comprehensive technical solutions in various fields, including CRO/CDMO drug impurity analysis, medical testing, food safety testing, and environmental monitoring [2] - The company has a strong technical foundation and credibility, enabling it to serve global partners effectively [2] - The company has not reported any preferred stock profit distribution plan for the reporting period [2] Group 2 - The company has changed its accounting firm to Lixin Certified Public Accountants (Special General Partnership) for the current reporting period [1] - The company has not experienced any need to restate or adjust previous accounting data [3] - There are no significant differences between the financial indicators disclosed in the quarterly and semi-annual reports [3]